UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report
(Date of
earliest event reported)
September 4, 2014
INOVIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-14888 |
|
33-0969592 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
660 W. Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania |
|
19462 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (267) 440-4200
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 3.01. |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
(d) On September 4, 2014, Inovio Pharmaceuticals, Inc. (the Company) provided notice to the NYSE MKT that the Company intends
to voluntarily transfer the listing of its common stock, par value $0.001 per share (the Common Stock), from NYSE MKT to the NASDAQ Global Select Market (NASDAQ). The Common Stock has been approved for listing on NASDAQ, and
the Company expects that the Common Stock will begin trading on NASDAQ on September 15, 2014. The Common Stock will continue to trade under the ticker symbol INO. Until the transfer of the listing to the NASDAQ is completed, the
Common Stock will continue to be traded on NYSE MKT.
Item 7.01. |
Regulation FD Disclosure. |
On September 4, 2014, the Company issued a press
release announcing that it plans to transfer the listing of its Common Stock from the NYSE MKT to NASDAQ as detailed in Item 3.01 above. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information contained in this Item 7.01 and Exhibit 99.1 to this report shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, as amended, except as may be expressly set forth by specific reference in such filing.
Item 9.01. |
Financial Statements and Exhibits. |
|
|
|
Exhibit No. |
|
Exhibit Description |
|
|
99.1 |
|
Press Release dated September 4, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
INOVIO PHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Peter Kies |
|
|
Peter Kies, |
|
|
Chief Financial Officer |
Date: September 4, 2014
-3-
Exhibit 99.1
NEWS RELEASE
Immediate Release
|
|
|
CONTACTS: |
|
|
Investors: |
|
Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com |
Media: |
|
Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com |
Inovio Pharmaceuticals to List on NASDAQ
PLYMOUTH MEETING, Pa. September 4, 2014 Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has met the listing criteria
for the NASDAQ Global Select Market and will transfer its U.S. stock exchange listing from the NYSE MKT to the NASDAQ Global Select Market on September 15, 2014. The company will retain its current ticker symbol, INO.
Dr. J. Joseph Kim, President and CEO, said, The majority of our peers are listed on NASDAQ, the worlds largest electronic stock market. We
expect this stock exchange will serve our investors well with respect to liquidity, pricing, speed of execution, and cost per trade. We also believe that the NASDAQ platform is an excellent vehicle for enhanced market visibility.
About Inovio Pharmaceuticals, Inc.
Inovio is
revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With
an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial
Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba. For more information, visit www.inovio.com.
* * *
This press release contains certain
forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set
forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in
this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies
and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be
indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA
vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, the adequacy of our capital resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to
develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the
company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the companys
technology by potential corporate or other partners or collaborators, capital market conditions including the trading market for our common stock on the NASDAQ Global Select Market, the impact of government healthcare proposals and other factors set
forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended June 30, 2014, and other regulatory filings from time to time. There can be no assurance that any product in
Inovios pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided
herein will be proven accurate.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024